Address
Paasheuvelweg 25a
Amsterdam, 1105 BP
United States of America (the)
Phone
31 20 240 6000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
209
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Matthew Craig Kapusta | Chief Executive Officer & Executive Director | 1.05M | 1972 |
| Jeannette Potts | Chief Legal & Compliance Officer and Corporate Secretary | 712,827 | 1962 |
| Richard Porter | Chief Business & Scientific Officer | 732,169 | 1968 |
| Christian Klemt | Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site | 759,950 | 1973 |
| Walid Abi-Saab | Chief Medical Officer | 945,278 | 1965 |
| Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | 0 | N/A |
| Chiara Elizabeth Russo | Senior Director of Investor Relations | 0 | N/A |
| Erin Boyer | Chief People & Culture Officer | 0 | N/A |
| Kylie O'Keefe | Chief Customer & Strategy Officer | 0 | 1985 |
| Tamara Tugal | Business Development Director | 0 | N/A |
| Amin Abujoub | Chief Technical Operations Officer | 0 | N/A |
uniQure N.V. is a pioneering gene therapy company dedicated to discovering and developing therapeutic solutions for individuals afflicted with severe genetic and other debilitating illnesses. Its flagship program, Etranacogene dezaparvovec (AMT-061), is currently in a pivotal Phase III HOPE-B clinical trial for treating hemophilia B. The company's robust pipeline extends to several other promising candidates, including AMT-130, a gene therapy undergoing Phase I/II studies for Huntington's disease, and AMT-060, also in Phase I/II for hemophilia B. Additionally, uniQure is advancing product candidates such as AMT-210 for Parkinson's disease, AMT-260 for temporal lobe epilepsy, the preclinical AMT-240 for autosomal dominant Alzheimer's disease, and AMT-161 for amyotrophic lateral sclerosis. Founded in 1998, uniQure N.V. is headquartered in Amsterdam, the Netherlands.